Immuto Scientific and the University of Wisconsin announced recently a collaborative agreement to identify disease-specific novel therapeutic targets in colorectal cancer using Immuto’s proprietary structural surfaceomics platform. “Our work with…

Immuto Scientific has entered into a research collaboration with an unnamed, U.S.-based multinational animal health company, the company announced today. According to a release, the collaboration is designed to apply…

Immuto Scientific has been awarded a $2.5 million Phase II SBIR grant from the National Institutes of Health (NIH), the company announced recently. According to a release, the grant will…

Immuto Scientific closed a $2.3 million seed funding round, the company announced recently. Wisconsin Investment Partners (WIP) led the round, with participation from the Wisconsin Alumni Research Foundation (WARF), Great Oaks…